[Nitric oxide and heart failure].
Yoshioka
Toru
T
Department of Organ Regeneration, Shinshu University Graduate School of Medicine.
Takahashi
Masafumi
M
Ikeda
Uichi
U
D000280:Administration, Inhalation; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D042783:Endothelial Cells / Q000201:enzymology / Q000378:metabolism; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D032383:Myocytes, Cardiac / Q000201:enzymology / Q000378:metabolism; D009569:Nitric Oxide / Q000008:administration & dosage / Q000096:biosynthesis / Q000502:physiology*; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D019001:Nitric Oxide Synthase / Q000502:physiology; D052248:Nitric Oxide Synthase Type I; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III
D000806:Angiotensin-Converting Enzyme Inhibitors; D020030:Nitric Oxide Donors; D009569:Nitric Oxide; C496320:NOS1 protein, human; C496319:NOS2 protein, human; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052248:Nitric Oxide Synthase Type I; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D007548:Isosorbide Dinitrate